Rivaroxaban, a new, oral, direct factor Xa inhibitor for thromboprophylaxis after major joint arthroplasty.
The new oral, antithrombotic drug rivaroxaban is a direct factor Xa inhibitor, which can restrict thrombin generation both in vitro and in vivo. It has a predictable dose-dependent pharmacokinetic and pharmacodynamic profile and is well tolerated. In patients undergoing total hip or knee arthroplasty, rivaroxaban, 10 mg once daily started 6 - 8 h after the operation, had a significantly better antithrombotic efficacy and a comparable safety when compared with enoxaparin. Furthermore in all studies performed the drug had no adverse influence on the liver function in comparison with enoxaparin. In conclusion, rivaroxaban is a potent and safe new compound for antithrombotic prophylaxis in orthopaedic surgery.
Borris
Lars C
LC
Arhus University Hospital, Department of Orthopaedics, Arhus C, Denmark. larsborr@rm.dk
D000284:Administration, Oral; D000818:Animals; D000990:Antithrombin III / Q000008:administration & dosage*; D001178:Arthroplasty / Q000009:adverse effects*; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000188:drug therapy* / Q000209:etiology / Q000517:prevention & control; D000069552:Rivaroxaban; D013876:Thiophenes / Q000008:administration & dosage*; D015912:Thrombolytic Therapy / Q000379:methods* / Q000639:trends
D009025:Morpholines; D013876:Thiophenes; D000990:Antithrombin III; D000069552:Rivaroxaban